I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| fibroblast | 14 studies | 26% ± 10% | |
| connective tissue cell | 6 studies | 30% ± 12% | |
| smooth muscle cell | 4 studies | 24% ± 11% | |
| GABAergic neuron | 3 studies | 17% ± 2% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 14 studies | 26% ± 10% | |
| connective tissue cell | 6 studies | 30% ± 12% | |
| smooth muscle cell | 4 studies | 24% ± 11% | |
| GABAergic neuron | 3 studies | 17% ± 2% |
Insufficient scRNA-seq data for expression of IL11RA at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 3039.10 | 245 / 245 | 100% | 9.23 | 502 / 502 |
| thymus | 100% | 4810.27 | 653 / 653 | 100% | 21.06 | 605 / 605 |
| brain | 96% | 1896.81 | 2542 / 2642 | 100% | 16.07 | 704 / 705 |
| uterus | 100% | 4162.70 | 170 / 170 | 96% | 14.37 | 439 / 459 |
| liver | 96% | 2316.68 | 217 / 226 | 99% | 10.88 | 400 / 406 |
| breast | 100% | 2982.83 | 459 / 459 | 93% | 6.15 | 1040 / 1118 |
| adrenal gland | 97% | 1312.45 | 249 / 258 | 95% | 10.03 | 218 / 230 |
| skin | 100% | 3290.88 | 1808 / 1809 | 90% | 11.12 | 423 / 472 |
| ovary | 100% | 3556.54 | 180 / 180 | 87% | 9.05 | 374 / 430 |
| kidney | 99% | 1824.11 | 88 / 89 | 86% | 4.88 | 779 / 901 |
| bladder | 100% | 2997.05 | 21 / 21 | 85% | 4.98 | 429 / 504 |
| lung | 99% | 2153.61 | 572 / 578 | 85% | 5.48 | 980 / 1155 |
| intestine | 100% | 4229.83 | 966 / 966 | 75% | 3.47 | 397 / 527 |
| pancreas | 67% | 578.76 | 221 / 328 | 96% | 6.78 | 170 / 178 |
| stomach | 98% | 2030.62 | 352 / 359 | 62% | 2.77 | 177 / 286 |
| esophagus | 98% | 2580.84 | 1417 / 1445 | 57% | 2.27 | 104 / 183 |
| eye | 0% | 0 | 0 / 0 | 100% | 18.61 | 80 / 80 |
| spleen | 100% | 3118.11 | 241 / 241 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 4148.15 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 100% | 2431.39 | 1200 / 1204 | 0% | 0 | 0 / 0 |
| heart | 99% | 3444.94 | 854 / 861 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 98% | 6.55 | 44 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 97% | 7.03 | 28 / 29 |
| muscle | 87% | 987.07 | 700 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 62% | 713.64 | 576 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0008284 | Biological process | positive regulation of cell population proliferation |
| GO_0019221 | Biological process | cytokine-mediated signaling pathway |
| GO_0060322 | Biological process | head development |
| GO_0038154 | Biological process | interleukin-11-mediated signaling pathway |
| GO_0032502 | Biological process | developmental process |
| GO_0009897 | Cellular component | external side of plasma membrane |
| GO_0043235 | Cellular component | receptor complex |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0019970 | Molecular function | interleukin-11 binding |
| GO_0004888 | Molecular function | transmembrane signaling receptor activity |
| GO_0004921 | Molecular function | interleukin-11 receptor activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | IL11RA |
| Protein name | Interleukin 11 receptor subunit alpha Interleukin-11 receptor subunit alpha Interleukin-11 receptor subunit alpha (IL-11 receptor subunit alpha) (IL-11R subunit alpha) (IL-11R-alpha) (IL-11RA) [Cleaved into: Soluble interleukin-11 receptor subunit alpha (sIL-11R) (sIL-11RA) (sIL11RA)] |
| Synonyms | |
| Description | FUNCTION: Receptor for interleukin-11 (IL11). The receptor systems for IL6, LIF, OSM, CNTF, IL11 and CT1 can utilize IL6ST for initiating signal transmission. The IL11/IL11RA/IL6ST complex may be involved in the control of proliferation and/or differentiation of skeletogenic progenitor or other mesenchymal cells (Probable). Essential for the normal development of craniofacial bones and teeth. Restricts suture fusion and tooth number. .; FUNCTION: [Soluble interleukin-11 receptor subunit alpha]: Soluble form of IL11 receptor (sIL11RA) that acts as an agonist of IL11 activity . The IL11:sIL11RA complex binds to IL6ST/gp130 on cell surfaces and induces signaling also on cells that do not express membrane-bound IL11RA in a process called IL11 trans-signaling . .; FUNCTION: [Isoform HCR2]: Soluble form of IL11 receptor (sIL11RA) that acts as an agonist of IL11 activity . The IL11:sIL11RA complex binds to IL6ST/gp130 on cell surfaces and induces signaling also on cells that do not express membrane-bound IL11RA in a process called IL11 trans-signaling . . |
| Accessions | ENST00000318041.13 [Q14626-1] ENST00000441545.7 [Q14626-1] ENST00000602473.5 [Q14626-2] ENST00000692788.1 ENST00000556792.5 ENST00000555981 G3V428 Q14626 G3V2J5 A0A8I5KTD7 G3V2A5 G3V3V2 ENST00000557298.5 ENST00000466082.2 ENST00000555247.5 ENST00000555981.6 [Q14626-1] G3V2G0 ENST00000555003.6 H0YCS8 A0A8J9AZZ3 G3V571 ENST00000553620.6 ENST00000690286.1 [Q14626-1] ENST00000685430.1 ENST00000556531.6 |
